AI assistant
Sending…
Climb Bio, Inc. — Director's Dealing 2024
Jun 28, 2024
33982_dirs_2024-06-28_38272fd9-d68b-4dbd-a34b-c88cb5b6939c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2024-06-26
Reporting Person: Dunn Judith (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-26 | Stock Option (Right To Buy) | $7.89 | A | 10000 | Acquired | 2034-06-25 | Common Stock (10000) | Direct |
Footnotes
F1: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.
More from Climb Bio, Inc.
Regulatory Filings
2026
May 29
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 5
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 3
Director's Dealing
2026
Feb 27
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2026
Feb 17
Director's Dealing
2026
Jan 8